Dokumentuaren aipamena
APA (7th ed.) Zitazioa
Tereshchenko, S. N., Shestakova, M. V., Ageev, F. T., Galstyan, G. R., Galyavich, A. S., Glezer, M. G., . . . Matskeplishvili, S. T. (2020). Rationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement. «FIRMA «SILICEA» LLC.
Ondo kopiatu da
Kopiatzeak huts egin du
Chicago Style (17th ed.) Zitazioa
Tereshchenko, S. N., et al. Rationale for Dapagliflozin Administration for the Prevention of Adverse Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. Expert Consensus Statement. «FIRMA «SILICEA» LLC, 2020.
Ondo kopiatu da
Kopiatzeak huts egin du
MLA (9th ed.) Zitazioa
Tereshchenko, S. N., et al. Rationale for Dapagliflozin Administration for the Prevention of Adverse Outcomes in Patients with Heart Failure with Reduced Ejection Fraction. Expert Consensus Statement. «FIRMA «SILICEA» LLC, 2020.
Ondo kopiatu da
Kopiatzeak huts egin du
Kontuz: berrikusi erreferentzia hauek erabili aurretik.